In partnership with Swiss teams specialized in the field of reproductive genetics, we can help you deal with genetic issues within your couple using the following methods: preimplantation diagnosis (PGD) and preimplantation genetic screening for aneuploidy (PGTa).
These innovative methods offer couples who suffer from a hereditary genetic disease, or who have difficulty conceiving, new prospects for fulfilling their desire for a child in complete safety.
Preimplantation diagnosis, also known as PGD, is a cutting-edge procedure that analyzes embryos obtained by in vitro fertilization (IVF) before they are implanted in the uterus. Its main aim is to detect any genetic or chromosomal abnormalities in the embryos, in order to select those that are healthy and able to develop normally. This prevents the transmission of serious genetic diseases to the offspring and improves the chances of IVF success.
PGD is generally recommended in cases where one or both members of the couple are carriers of a known genetic abnormality. Embryos obtained by IVF are developed in the laboratory for a few days, after which one or more cells are harvested for analysis. The diagnostic techniques used may vary, but they all aim to identify the specific genetic anomalies sought. Once the results are available, only healthy embryos free of the anomaly in question are selected for transfer to the woman’s uterus. Preimplantation genetic screening aneuploidy, or PGTa, is a variant of PGD that focuses specifically on the detection of chromosomal abnormalities, such as aneuploidies. Aneuploidies are alterations in the number of chromosomes in an embryo, such as trisomy 21 (Down syndrome) or monosomy X (Turner syndrome). These chromosomal anomalies are often associated with early spontaneous abortions or developmental problems.